On May 21, Benchmark reiterated its Buy rating on Silicon Laboratories Inc. (NASDAQ:SLAB) stock, keeping the price target at $160.
Cody Acree from Benchmark Co. kept its rating on SLAB after assessing the company’s market position and future growth prospects following Q1 outcomes. The company’s revenue of $178 million during Q1 2025 was 7% higher than Q4 2024 and 67% higher year-over-year.
A technician looking at a circuit board of analog semiconductor products.
Acree pointed out the company’s strong foothold in the semiconductor industry, driven by its innovative product offerings and strategic initiatives to expand its market share. The company began the production of its first device in its next-generation Series 3 platform on 22nm process technology. This series will be an upgrade of Series 2 with higher computing power and AI capabilities. The company is also advancing the production of its MG26 family of wireless SoCs, empowering developers to design future-proof Matter applications.
The analyst remains optimistic about SLAB as he considers its strong revenue streams to be a key growth factor. Silicon Laboratories’ Home and Life business almost doubled year-over-year during Q1, posting revenue of around $82 million. The Industrial and Commercial business also experienced double-digit growth from a year ago, posting $96 million in revenues.
Silicon Laboratories Inc. (NASDAQ:SLAB) is a fabless semiconductor company that is engaged in secure, intelligent wireless technology for a connected world. Its integrated hardware and software systems allow customers to build advanced industrial, commercial, home, and life applications.
While we acknowledge the potential of SLAB to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLAB and that has 100x upside potential, check out our report about this cheapest AI stock.
Read Next: 30 Best Stocks to Buy Now According to Billionaires and 15 Small-Cap Healthcare Stocks Hedge Funds Are Buying.
Disclosure. None.
 stock, keeping the price target at $160. Cody Acree from Benchmark Co. kept its rating on SLAB after assessing the company’s market position and future growth prospects following Q1 outcomes. The company’s revenue of $178 million during Q1 2025 was 7% higher […]){kind=link}